Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)

OBJECTIVES: Single-pill combination therapy (amlodipine/atorvastatin) might be more effective than double-pill therapy (amlodipine+atorvastatin) in patients with diabetes and concomitant hypertension requiring statin therapy. We compared the cost-effectiveness of a single-pill with that of double-pi...

Full description

Bibliographic Details
Main Authors: Ji-Hyun Park, Yong-Ho Lee, Su-Kyoung Ko, Bong-Soo Cha
Format: Article
Language:English
Published: Korean Society of Epidemiology 2015-02-01
Series:Epidemiology and Health
Subjects:
Online Access:http://www.e-epih.org/upload/pdf/epih-37-e2015010.pdf
_version_ 1828408370547130368
author Ji-Hyun Park
Yong-Ho Lee
Su-Kyoung Ko
Bong-Soo Cha
author_facet Ji-Hyun Park
Yong-Ho Lee
Su-Kyoung Ko
Bong-Soo Cha
author_sort Ji-Hyun Park
collection DOAJ
description OBJECTIVES: Single-pill combination therapy (amlodipine/atorvastatin) might be more effective than double-pill therapy (amlodipine+atorvastatin) in patients with diabetes and concomitant hypertension requiring statin therapy. We compared the cost-effectiveness of a single-pill with that of double-pill for control of low density lipoprotein cholesterol (LDL-C) levels, with the ultimate goal of cardiovascular disease prevention, in these patients using a cost-effectiveness analysis model that considered medication adherence. METHODS: Effectiveness was defined as the percentage (%) attainment of target LDL-C levels (<100 mg/dL) based on adherence for each therapy. Adherence was defined as compliance to medication (≥80% proportion of days covered). A systematic review of the literature was conducted to determine the proportion of patients who were adherent and target goal attainment based on adherence level. The annual medication costs were based on the adherence levels for each regimen. The average cost-effectiveness ratio (ACER) was calculated as the cost per % attainment of the target LDL-C level. RESULTS: The ACER for the single-pill regimen was lower than for the double-pill regimen (4,123 vs. 6,062 Korean won per 1% achievement of target goal). Compared with the double-pill, the medication costs were approximately 32% lower with the single-pill. CONCLUSION:A single-pill for reductions in LDL-C is cost-effective compared with double-pill in hypertensive patients with type 2 diabetes.
first_indexed 2024-12-10T11:37:48Z
format Article
id doaj.art-b836c2455d104d7190bb0ad07fbb6471
institution Directory Open Access Journal
issn 2092-7193
language English
last_indexed 2024-12-10T11:37:48Z
publishDate 2015-02-01
publisher Korean Society of Epidemiology
record_format Article
series Epidemiology and Health
spelling doaj.art-b836c2455d104d7190bb0ad07fbb64712022-12-22T01:50:21ZengKorean Society of EpidemiologyEpidemiology and Health2092-71932015-02-013710.4178/epih/e2015010776Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)Ji-Hyun Park0Yong-Ho Lee1Su-Kyoung Ko2Bong-Soo Cha3 Pfizer Pharmaceuticals Korea Ltd., Seoul, Korea Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Pfizer Pharmaceuticals Korea Ltd., Seoul, Korea Department of Internal Medicine, Yonsei University College of Medicine, Seoul, KoreaOBJECTIVES: Single-pill combination therapy (amlodipine/atorvastatin) might be more effective than double-pill therapy (amlodipine+atorvastatin) in patients with diabetes and concomitant hypertension requiring statin therapy. We compared the cost-effectiveness of a single-pill with that of double-pill for control of low density lipoprotein cholesterol (LDL-C) levels, with the ultimate goal of cardiovascular disease prevention, in these patients using a cost-effectiveness analysis model that considered medication adherence. METHODS: Effectiveness was defined as the percentage (%) attainment of target LDL-C levels (<100 mg/dL) based on adherence for each therapy. Adherence was defined as compliance to medication (≥80% proportion of days covered). A systematic review of the literature was conducted to determine the proportion of patients who were adherent and target goal attainment based on adherence level. The annual medication costs were based on the adherence levels for each regimen. The average cost-effectiveness ratio (ACER) was calculated as the cost per % attainment of the target LDL-C level. RESULTS: The ACER for the single-pill regimen was lower than for the double-pill regimen (4,123 vs. 6,062 Korean won per 1% achievement of target goal). Compared with the double-pill, the medication costs were approximately 32% lower with the single-pill. CONCLUSION:A single-pill for reductions in LDL-C is cost-effective compared with double-pill in hypertensive patients with type 2 diabetes.http://www.e-epih.org/upload/pdf/epih-37-e2015010.pdfAtorvastatin calciumAmlodipine besylateMedication adherenceLow density lipoprotein cholesterolCost-effectiveness analysis
spellingShingle Ji-Hyun Park
Yong-Ho Lee
Su-Kyoung Ko
Bong-Soo Cha
Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
Epidemiology and Health
Atorvastatin calcium
Amlodipine besylate
Medication adherence
Low density lipoprotein cholesterol
Cost-effectiveness analysis
title Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
title_full Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
title_fullStr Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
title_full_unstemmed Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
title_short Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)
title_sort cost effectiveness analysis of low density lipoprotein cholesterol lowering therapy in hypertensive patients with type 2 diabetes in korea single pill regimen amlodipine atorvastatin versus double pill regimen amlodipine atorvastatin
topic Atorvastatin calcium
Amlodipine besylate
Medication adherence
Low density lipoprotein cholesterol
Cost-effectiveness analysis
url http://www.e-epih.org/upload/pdf/epih-37-e2015010.pdf
work_keys_str_mv AT jihyunpark costeffectivenessanalysisoflowdensitylipoproteincholesterolloweringtherapyinhypertensivepatientswithtype2diabetesinkoreasinglepillregimenamlodipineatorvastatinversusdoublepillregimenamlodipineatorvastatin
AT yongholee costeffectivenessanalysisoflowdensitylipoproteincholesterolloweringtherapyinhypertensivepatientswithtype2diabetesinkoreasinglepillregimenamlodipineatorvastatinversusdoublepillregimenamlodipineatorvastatin
AT sukyoungko costeffectivenessanalysisoflowdensitylipoproteincholesterolloweringtherapyinhypertensivepatientswithtype2diabetesinkoreasinglepillregimenamlodipineatorvastatinversusdoublepillregimenamlodipineatorvastatin
AT bongsoocha costeffectivenessanalysisoflowdensitylipoproteincholesterolloweringtherapyinhypertensivepatientswithtype2diabetesinkoreasinglepillregimenamlodipineatorvastatinversusdoublepillregimenamlodipineatorvastatin